Similar results were obtained in vivo in the immunocompetent transgenic neuroblastoma mouse model Th-MYCN, which closely recapitulates the main features of poor outcome human neuroblastoma, as well as immunocompromised mouse model. This evidence concerns the gene MYCN and neuroblastoma.